Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45,575 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre-transplantation for Ph+ acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study.
Liu H, Xu H, Chi P, Feng Z, Xu X, Nie D, Li X, Liang X, Fan Z, Xu N, Huang F, Lin R, Wang Z, Jin H, Zhou H, Guo X, Lin D, Sun J, Liu Q, Xuan L. Liu H, et al. Among authors: sun j. Am J Hematol. 2025 Jan;100(1):33-37. doi: 10.1002/ajh.27516. Epub 2024 Nov 16. Am J Hematol. 2025. PMID: 39548804
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, Zhang Y, Huang F, Zhou H, Fan Z, Tu S, Li Y, Guo X, Yu G, Liu Q. Liu H, et al. Among authors: sun j. J Hematol Oncol. 2013 Feb 8;6:15. doi: 10.1186/1756-8722-6-15. J Hematol Oncol. 2013. PMID: 23394705 Free PMC article. Clinical Trial.
Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data.
Yu S, Huang F, Fan Z, Xuan L, Nie D, Xu Y, Yang T, Wang S, Jiang Z, Xu N, Lin R, Ye J, Lin D, Sun J, Huang X, Wang Y, Liu Q. Yu S, et al. Among authors: sun j. J Hematol Oncol. 2020 Mar 12;13(1):18. doi: 10.1186/s13045-020-00859-5. J Hematol Oncol. 2020. PMID: 32164760 Free PMC article. Clinical Trial.
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
Liu H, Huang F, Zhang Y, Wu M, Xu N, Fan Z, Sun Z, Li X, Lin D, Xiong Y, Liu X, Lin R, Shi P, Xu J, Wang Z, Li X, Sun J, Liu Q, Xuan L. Liu H, et al. Among authors: sun z, sun j. Am J Hematol. 2023 Mar;98(3):408-412. doi: 10.1002/ajh.26800. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588387 Free article. Clinical Trial.
Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation.
Jiang Z, Fan Z, Zhang T, Lin R, Xu H, Xu N, Huang F, Chi P, Ou X, Wang Z, Liu H, Zhao K, Jiang L, Yu S, Sun J, Liu Q, Xuan L. Jiang Z, et al. Among authors: sun j. Br J Haematol. 2024 Apr;204(4):1393-1401. doi: 10.1111/bjh.19282. Epub 2024 Jan 2. Br J Haematol. 2024. PMID: 38168845
45,575 results
You have reached the last available page of results. Please see the User Guide for more information.